Fortress Biotech旗下子公司Cyprium Therapeutics近日签署重要协议，将其持有的罕见儿科疾病优先审评凭证以2.05亿美元价格售出。这项交易标志着生物制药领域资产货币化的典型案例。
优先审评券制度由美国FDA设立，旨在激励药企研发针对罕见儿科疾病的创新疗法。持有者可通过该凭证加速其他新药上市审评流程。此次交易不仅为Cyprium带来可观现金流，更凸显出稀有监管资产在医药市场的巨大价值。
随着全球医药监管环境持续优化，此类优先审评券已成为稀缺资源。本次交易金额创下同类资产转让的新高，预计将对生物科技行业的资产估值体系产生深远影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.